---
title: "Moleculin reports interim results from MIRACLE trial in r/r AML patients"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294705884.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-08-03T10:14:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294705884.md)
  - [en](https://longbridge.com/en/news/294705884.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294705884.md)
generator: "portal-rs"
---

# Moleculin reports interim results from MIRACLE trial in r/r AML patients

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [MBRX.US](https://longbridge.com/en/quote/MBRX.US.md)

## Related News & Research

- [Moleculin Biotech announces annual shareholder meeting](https://longbridge.com/en/news/296828733.md)
- [Moleculin Biotech reports interim MIRACLE trial data showing higher remission rates in relapsed/refractory AML](https://longbridge.com/en/news/295935232.md)
- [BioMarin spends up to $490m for Alesta’s bone disease candidate](https://longbridge.com/en/news/296381315.md)
- [Kynexis pockets €97m to advance cognition-focused schizophrenia drug](https://longbridge.com/en/news/296501085.md)
- [Netflix parts ways with a key ad exec in a leadership shake-up. Read the leaked memo from its ad chief.](https://longbridge.com/en/news/296834043.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**